胰高血糖素样肽-1受体激动剂对代谢功能障碍相关脂肪性肝病肝硬化合并2型糖尿病患者不良肝脏结局风险的影响
基于MarketScan数据库的回顾性队列研究,纳入459例启动GLP-1RAs和4837例未启动GLP-1RAs的MASLD肝硬化合并2型糖尿病患者。经重叠倾向评分加权调整后,GLP-1RAs启动与复合不良肝脏结局风险降低36%相关(HR 0.64,95%CI 0.54-0.76),肝失代偿、门静脉高压、肝细胞癌和肝移植风险均显著降低。
要点
- GLP-1RAs启动与MASLD肝硬化合并2型糖尿病患者复合不良肝脏结局风险降低36%相关(HR 0.64,95%CI 0.54-0.76)。
- GLP-1RAs启动与肝细胞癌风险降低相关(HR 0.37,95%CI 0.20-0.63)。
- GLP-1RAs启动与肝移植风险降低相关(HR 0.24,95%CI 0.12-0.43)。
核心结论
- 在MASLD肝硬化合并2型糖尿病患者中,使用GLP-1RAs与长期不良肝脏结局(包括肝失代偿、门静脉高压、肝细胞癌和肝移植)风险显著降低相关。
研究设计与样本
- 回顾性队列研究,使用MarketScan数据库2012年至2020年MASLD肝硬化合并2型糖尿病患者数据。
- 采用Cox比例风险模型分析GLP-1RAs启动(作为时间依赖变量)与不良肝脏结局风险的关联。
- 使用重叠倾向评分加权(OPSW)控制混杂。
- 共纳入459例GLP-1RAs患者和4837例非GLP-1RAs患者。
主要发现
- 非GLP-1RAs患者随访7431.7人年期间发生1411例(29%)不良肝脏结局,GLP-1RAs患者随访586.6人年期间发生32例(7%)不良肝脏结局,风险率差为每100人年13.5(95%CI 11.4-15.7)。
- OPSW调整后,GLP-1RAs启动患者相比未启动患者不良肝脏结局风险降低36%(HR 0.64,95%CI 0.54-0.76)。
- GLP-1RAs启动与肝失代偿调整后风险显著降低相关(HR 0.74,95%CI 0.61-0.88)。
- GLP-1RAs启动与门静脉高压调整后风险显著降低相关(HR 0.73,95%CI 0.60-0.88)。
- GLP-1RAs启动与肝细胞癌调整后风险显著降低相关(HR 0.37,95%CI 0.20-0.63),与肝移植调整后风险显著降低相关(HR 0.24,95%CI 0.12-0.43)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: We examined the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) initiation on long-term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real-world data from the MarketScan database. METHODS: We conducted a retrospective cohort study of patients with MASLD cirrhosis and type 2 diabetes between 2012 and 2020. Cox proportional hazard models examine the association between GLP-1RAs initiation, modelled as time-dependent, and the risk of ALO, a composite endpoint defined by the first occurrence of hepatic decompensation(s), portal hypertension, hepatocellular carcinoma (HCC) or liver transplantation (LT). We used Overlap Propensity Score Weighting (OPSW) to account for confounding. The study included 459 GLP-1RAs and 4837 non-GLP-1RAs patients. RESULTS: The non-GLP-1RAs patients presented with 1411 (29%) ALO over 7431.7 person years, while GLP-1RAs patients had 32 (7%) ALO over 586.6 person years - risk rate difference 13.5 (95% CI: 11.4-15.7) per 100 person-years. The OPSW-adjusted risk of ALO was reduced by 36% (hazard ratio [HR]: 0.64; 95% CI: 0.54-0.76) in patients with vs. without GLP-1RAs initiation. GLP-1RAs initiation was associated with significant reductions in the adjusted risk of hepatic decompensation (HR: 0.74; 95% CI: 0.61-0.88), portal hypertension (HR: 0.73; 95% CI: 0.60-0.88), HCC (HR: 0.37; 95% CI: 0.20-0.63) and LT (HR: 0.24; 95% CI: 0.12-0.43). CONCLUSION: The use of GLP-1RAs was associated with significant risk reductions in long-term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC and LT, in MASLD cirrhosis patients with type 2 diabetes.
引用
- Elsaid MI, Li N, Firkins SA, et al. Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes. Aliment Pharmacol Ther. 2024. PMID: 38538967. doi:10.1111/apt.17925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。